IMV Inc. (IMV.TO)
| Previous Close | 2.8600 |
| Open | 2.8400 |
| Bid | 2.7300 x 0 |
| Ask | 2.7700 x 0 |
| Day's Range | 2.7000 - 2.8600 |
| 52 Week Range | 2.7000 - 19.3000 |
| Volume | |
| Avg. Volume | 21,828 |
| Market Cap | 32.018M |
| Beta (5Y Monthly) | 1.35 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6690 |
| Earnings Date | Mar 14, 2023 - Mar 20, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.74 |
- Business Wire
IMV Inc. Announces Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S
DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass., January 08, 2023--IMV Inc. (Nasdaq: IMV; TSX: IMV) ("IMV" or the "Company"), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today outlined its planned 2023 milestones to advance the clinical development of its lead therapeutic, maveropepimut-S (MVP-S).
- Business Wire
IMV Announces Closing of US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., December 20, 2022--IMV Inc. ("IMV" or the "Company") (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company advancing a portfolio of therapies based on the Company’s immune-educating platform, DPX®, to potentially treat solid and hematologic cancers, announced today the closing of its previously announced registered direct offering (the "Offering") for the sale of an aggregate of 3,448,276 common shares (or common share equivalents) (each,
- Business Wire
IMV Announces US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., December 16, 2022--IMV Inc. ("IMV" or the "Company") (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company advancing a portfolio of therapies based on the Company’s immune-educating platform, DPX®, to potentially treat solid and hematologic cancers, announced today that it has entered into definitive agreements for the sale of an aggregate of 3,448,276 common shares (or common share equivalents) (each, a "Share" and, collectively, the "Sha
